1.	Phase IV Study of Amifostine for Chemotherapy Induced Peripheral Neuropathy in Patients with Cancer (Summary Last Modified 04/2000) Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RNSMC-AM9702, ALZA-RNSMC-AM9702, NCI-V98-1390, NCT00003252
2.	Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Phase: Phase IV Type: Supportive care Status: Temporarily closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: SUN-2011-DP, NCT01288625
3.	Phase II/III Randomized Study of Amifostine Followed By Protracted Fractionated Radiotherapy in Patients With Inoperable, Unresectable, or Postoperatively Recurrent Rectal Adenocarcinoma (Summary Last Modified 11/2001) Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Completed Age: 18 to physiologic 74 Sponsor: NCI Protocol IDs: UPCC-00-A-0465, NCI-T87-0232
4.	Phase I Pilot/Phase III Randomized Study of CDDP and Combined External-Beam/Intracavitary Radiotherapy with vs without WR-2721 in Patients with Stages IIA-IVA and Selected Stage IB Carcinoma of the Uterine Cervix Phase: Phase III, Phase I Type: Supportive care, Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: AECM-8908198, NCI-V92-0084
5.	Phase III Randomized Study of Radiotherapy with vs without Amifostine for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 04/98) Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: USB-WR-38, NCI-V96-1083
6.	Phase III Randomized Study of Amifostine in Reducing Cisplatin Induced Ototoxicity in Cancer Patients Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UCMC-971163, ALZA-UCMC-971163, NCI-V97-1330
7.	Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000066260, RTOG-9801, NCT00003313
8.	Phase III Randomized Study of Pentoxifylline, Ciprofloxacin, and Dexamethasone Versus Amifostine in Patients with Myelodysplastic Syndromes (Summary Last Modified 08/1998) Phase: Phase III Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BOSTON-VAMC-523, ALZA-97-047-ii, NCI-V98-1422
9.	Phase III Randomized Comparison of CACP vs CACP plus WR-2721 in Patients with Disseminated Malignant Melanoma Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: EST-1686
10.	Phase III Study of High-Dose CTX plus GM-CSF with vs without WR-2721 Chemoprotection in Patients with Advanced Malignancies Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CLB-9160, CALGB-9160
11.	Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000285700, GOG-0192, NCT00058071
12.	Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 2004.00, NCI-2009-01543, FHCRC-2004.00, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
13.	Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Phase: Phase III Type: Treatment Status: Temporarily closed Age: 18 and under Sponsor: NCI, Other Protocol IDs: CDR0000454849, COG-ARAR0331, ARAR0331, NCT00274937
14.	Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: NU 97CC4, NCI-G99-1633, NCT00004166
15.	Phase I/II Study of High Dose Paclitaxel, Cyclophosphamide, and Cisplatin Conditioning, Amifostine Cytoprotection, Purified Autologous Hematopoietic Progenitor/Stem Cell Transplantation, and Posttransplant Immunomodulation with an Anti-Idiotype Vaccine in Patients with Metastatic Breast Cancer (Summary Last Modified 09/98) Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: UKMC-96BMT59, ALZA-UKMC-96BMT59, NCI-V97-1332
16.	Phase I/II Study of Amifostine in Patients with Myelodysplasia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-97076, ALZA-97-013-ii, NCI-G97-1338
17.	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 65 and under Sponsor: Other Protocol IDs: 8433, UCCRC-8433, ALZA-97-005-ii, NCI-V97-1357, NCT00003136
18.	Phase I/II Study of Amifostine in Ameliorating Chronic Toxicity of Fludarabine Monophosphate Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UARIZ-HSC-97116, ALZA-UARIZ-HSC-97116, NCI-V98-1371
19.	Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000066028, MGH-M7-20, ALZA-97-024-ii, NCI-V98-1384, NCT00003193
20.	Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000066087, P30CA016042, UCLA-HSPC-970304601B, ALZA-UCLA-HSPC-970304601B, NCI-G98-1390, NCT00003225
21.	Phase I/II Study of Amifostine in Combination with Cisplatin, Paclitaxel, and Radiation Therapy in Patients with Locally Advanced, Unresectable Head and Neck Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UIC-H-97-783, ALZA-UIC-H-97-783, NCI-V98-1389, NCT00003251
22.	Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 14 to 70 Sponsor: Other Protocol IDs: UKMC-97BMT72, CDR0000066448, ALZA-UKMC-97BMT72, NCI-V98-1455, NCT00003425
23.	Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: EPROST-88191, SCCC-1988007, ALZA-97-052-ii, BHM-98-32, NCI-V98-1474, SCCC-97098, NCT00003582
24.	Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068021, NCCTG-N9923, N9923, NCT00006012
25.	Radiation Therapy and Cisplatin With or Without Amifostine in Treating Patients With Stage IIIB or Stage IVA Cancer of the Cervix Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068472, RTOG-C-0116, RTOG-0116, NCT00012012